Home - IAVI - International AIDS Vaccine Initiative

Translating scientific discoveries into
affordable, accessible public health solutions

new approaches to developing vaccines and other means of preventing HIV.

translational and clinical research through our laboratories in the U.S., India, and the U.K.

in-country for researching vaccine candidates while strengthening local public health and scientific expertise.

with industry and enlist biopharma product development skills to develop innovative products tailored to target populations.

IAVI’s resources with other innovators to help the HIV community as a whole succeed.

IAVI’s core capabilities to solving disease prevention and treatment challenges.

New partnership aims to make antibody prophylaxis for HIV more feasible and affordable.

Collaboration to develop optimal combination of HIV-specific antibodies and ensure that cost is not a barrier to access

Phase I trial to evaluate safety and immunogenicity of vaccine candidate engineered to elicit targeted immune response against HIV.

Data from two Phase II clinical trials conducted by Aeras and partners indicate promise for future of TB vaccine development.

After decades of research, renewed promise emerges for developing vaccines against the world’s deadliest infectious disease.

IAVI staff explain why an HIV vaccine is the best way to end to the epidemic.

Publications